Address
Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
Phone
32 1 534 29 00
Website
Sector
Healthcare
Industry
Biotechnology
Employees
452
First IPO Date
February 27, 2012
| Name | Title | Pay | Year Born |
| Henry Gosebruch | Chief Executive Officer & Executive Director | 1.1M | N/A |
| Annelies Missotten | Executive Officer | 723,017 | 1973 |
| Ellen Van Der Aar | Head of Development | 0 | N/A |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy | 0 | N/A |
| Marieke Vermeersch | Head of Corporation Communication | 0 | N/A |
| Glenn Schulman | Head of Investor Relations | 0 | N/A |
| Jeevan Shetty | Head of Clinical Development Oncology | 0 | N/A |
| Fred W. Blakeslee | Executive Vice President & General Counsel | 0 | N/A |
| Tania Philipp | Chief Human Resources Officer | 0 | 1972 |
| Aaron L. Cox | Chief Financial Officer | 0 | 1984 |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.